Glycoprotein 41 (gp41) - Drugs in Development, 2021
Glycoprotein 41 (gp41) - Drugs in Development, 2021
SUMMARY
According to the recently published report 'Glycoprotein 41 - Drugs In Development, 2021'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 18 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.
The report 'Glycoprotein 41 - Drugs In Development, 2021' outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Glycoprotein 41 - Drugs In Development, 2021'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 18 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.
The report 'Glycoprotein 41 - Drugs In Development, 2021' outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Glycoprotein 41 (gp41) - Overview
Glycoprotein 41 (gp41) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycoprotein 41 (gp41) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
Frontier Biotechnologies Inc
Longevity Biotech Inc
Minka Therapeutics SA
Molecular Express Inc
Mymetics Corp
Navigen Inc
Novodux
Osel Inc
Protheragen Inc
Glycoprotein 41 (gp41) - Drug Profiles
albuvirtide LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPT-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human immunodeficiency virus (virus like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-5001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPER-656 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYMV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-3S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycoprotein 41 (gp41) - Dormant Products
Glycoprotein 41 (gp41) - Discontinued Products
Glycoprotein 41 (gp41) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2021: Frontier biotechnologies first long-acting injectable (Aikening), in a two drug regimen for HIV, proves safe and efficacious for patients
Dec 10, 2019: Navigen announces FDA clearance of its IND application to initiate first-in-human studies for CPT31, a novel, D-peptide HIV entry inhibitor
Apr 29, 2019: Mymetics receives funding from NIH for Novel HIV Vaccine Study
Aug 21, 2018: Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA
Jun 07, 2018: Frontier Biotech receives marketing authorization from China FDA for Aikening (albuvirtide for injection), China's first new drug for the treatment of HIV
Sep 18, 2017: Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31
Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science
Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen’s HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate
Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial
May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US
Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed
Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Glycoprotein 41 (gp41) - Overview
Glycoprotein 41 (gp41) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycoprotein 41 (gp41) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
Frontier Biotechnologies Inc
Longevity Biotech Inc
Minka Therapeutics SA
Molecular Express Inc
Mymetics Corp
Navigen Inc
Novodux
Osel Inc
Protheragen Inc
Glycoprotein 41 (gp41) - Drug Profiles
albuvirtide LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPT-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human immunodeficiency virus (virus like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-5001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPER-656 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYMV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-3S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycoprotein 41 (gp41) - Dormant Products
Glycoprotein 41 (gp41) - Discontinued Products
Glycoprotein 41 (gp41) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2021: Frontier biotechnologies first long-acting injectable (Aikening), in a two drug regimen for HIV, proves safe and efficacious for patients
Dec 10, 2019: Navigen announces FDA clearance of its IND application to initiate first-in-human studies for CPT31, a novel, D-peptide HIV entry inhibitor
Apr 29, 2019: Mymetics receives funding from NIH for Novel HIV Vaccine Study
Aug 21, 2018: Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA
Jun 07, 2018: Frontier Biotech receives marketing authorization from China FDA for Aikening (albuvirtide for injection), China's first new drug for the treatment of HIV
Sep 18, 2017: Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31
Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science
Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen’s HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate
Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial
May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US
Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed
Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Frontier Biotechnologies Inc, 2021
Pipeline by Longevity Biotech Inc, 2021
Pipeline by Minka Therapeutics SA, 2021
Pipeline by Molecular Express Inc, 2021
Pipeline by Mymetics Corp, 2021
Pipeline by Navigen Inc, 2021
Pipeline by Novodux, 2021
Pipeline by Osel Inc, 2021
Pipeline by Protheragen Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Frontier Biotechnologies Inc, 2021
Pipeline by Longevity Biotech Inc, 2021
Pipeline by Minka Therapeutics SA, 2021
Pipeline by Molecular Express Inc, 2021
Pipeline by Mymetics Corp, 2021
Pipeline by Navigen Inc, 2021
Pipeline by Novodux, 2021
Pipeline by Osel Inc, 2021
Pipeline by Protheragen Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
